Core Viewpoint - Grace Therapeutics, Inc. is advancing GTx-104, a novel injectable formulation of nimodipine for intravenous infusion aimed at addressing unmet medical needs in patients with aneurysmal subarachnoid hemorrhage (aSAH) [1] Company Overview - Grace Therapeutics is a late-stage biopharma company focused on drug candidates for rare and orphan diseases, with a lead clinical asset, GTx-104, targeting aSAH [7] - The company has received Orphan Drug Designation from the FDA for its lead clinical assets, providing seven years of marketing exclusivity post-launch in the U.S. under certain conditions [7] Product Details - GTx-104 is designed for IV infusion in aSAH patients, utilizing unique nanoparticle technology to facilitate the aqueous formulation of insoluble nimodipine [6] - The product aims to improve tolerability and dosing consistency compared to oral nimodipine, potentially eliminating the need for nasogastric tube administration in unconscious or dysphagic patients [6] Clinical Trial Insights - The STRIVE-ON trial (NCT05995405) compared GTx-104 with oral nimodipine in hospitalized aSAH patients, showing a 19% reduction in clinically significant hypotension episodes for GTx-104 [4] - Key findings include that 54% of patients on GTx-104 achieved a relative dose intensity of 95% or higher, compared to only 8% on oral nimodipine, and 29% more patients on GTx-104 had favorable functional outcomes at 90 days [4] Conference Participation - Grace Therapeutics will present findings at two major medical conferences in March 2026, discussing the unmet medical needs in aSAH and the potential benefits of GTx-104 [2][3]

Summary of Grace Therapeutics FY Conference Call Company Overview - **Company**: Grace Therapeutics (NasdaqCM:GRCE) - **Focus**: Development of GTx-104 for the treatment of aneurysm subarachnoid hemorrhage (aSAH) - **PDUFA Date**: April 23, 2026, for GTx-104 approval Core Industry Insights - **Disease Context**: aSAH is a critical care condition with high mortality (one-third of patients do not survive) and morbidity (one-third suffer long-term effects) [3][4] - **Current Treatment**: The only FDA-approved drug for aSAH is nimodipine, which is administered orally and has significant limitations, including a dosing burden and poor pharmacokinetics [4][6] GTx-104 Innovation - **Formulation**: GTx-104 is the first aqueous formulation of nimodipine that can be administered via intravenous infusion, addressing the challenges of the oral formulation [5] - **Clinical Advantages**: - Over 90% of patients on oral nimodipine do not receive the full therapeutic dose due to hypotension and other complications [6][7] - IV administration shows better pharmacokinetics, with a 2-3x lower variability compared to oral [7][8] - Improved ICU workload management and reduced complications associated with oral administration [9] STRIVE-ON Study - **Study Design**: Phase 3 safety trial comparing IV GTx-104 to oral nimodipine, involving 100 patients across 30 high-volume academic centers [12][13] - **Primary Endpoint**: Clinically significant hypotension events; IV arm showed almost 20% fewer events compared to oral [15] - **Relative Dose Intensity (RDI)**: 55% of IV patients achieved 95% or higher RDI, compared to only 8% in the oral group [16] - **Efficacy Signals**: Nearly 30% of IV patients showed good functional recovery, with zero bedridden patients at day 90 compared to 15-16% in the oral arm [17][18] Key Opinion Leader (KOL) Feedback - KOLs are enthusiastic about the potential for better hypotension control and higher dose compliance with GTx-104, which may lead to improved patient outcomes [19] Regulatory and Market Strategy - **Regulatory Engagement**: Positive interactions with the FDA leading up to the NDA submission, with no alarming issues raised [23] - **Market Education**: Ongoing efforts to educate healthcare professionals about the limitations of oral nimodipine and the benefits of GTx-104, including two major continuing medical education events attended by 10,000 healthcare professionals [25][26] Market Potential - **Patient Population**: Estimated 45,000 cases of aSAH annually in the U.S., with a focus on severe cases (Hunt and Hess grades 3-5) [32][41] - **Value Proposition**: Emphasis on hemodynamic stability, reliable drug exposure, and reduced ICU workload [33] Pricing Strategy - Ongoing work to determine pricing for GTx-104, considering the current market for oral nimodipine and the need to maximize patient access [34][36] Intellectual Property - **Protection**: Orphan drug designation expected to convert to exclusivity upon approval, with patents extending to 2043 for method of use and 2037 for formulations [43][44] Conclusion - Grace Therapeutics is positioned to potentially transform the treatment landscape for aSAH with GTx-104, addressing significant limitations of current therapies and aiming for a strong market entry following FDA approval.

Core Insights - Grace Therapeutics, Inc. announced that the abstract of its Pivotal Phase 3 STRIVE-ON Safety Trial for GTx-104 has been accepted for late-breaking presentation at the Society of Vascular and Interventional Neurology annual meeting [1][2] Company Overview - Grace Therapeutics is a late-stage biopharma company focused on developing drug candidates for rare and orphan diseases, with a lead clinical asset, GTx-104, targeting aneurysmal subarachnoid hemorrhage (aSAH) [5] - The company utilizes novel drug delivery technologies aimed at improving the performance of existing drugs, achieving faster onset of action, enhanced efficacy, and reduced side effects [5] Product Details - GTx-104 is a clinical-stage injectable formulation of nimodipine designed for IV infusion in aSAH patients, addressing significant unmet medical needs [4] - The unique nanoparticle technology of GTx-104 allows for an aqueous formulation of insoluble nimodipine, facilitating standard peripheral IV infusion [4] - GTx-104 has been administered to over 200 patients and healthy volunteers, demonstrating good tolerance and significantly lower pharmacokinetic variability compared to oral nimodipine [4] Clinical Trial Information - The STRIVE-ON trial (NCT05995405) focuses on the safety and tolerability of GTx-104 compared to oral nimodipine in patients with aSAH [3] - The oral presentation of the trial results is scheduled for November 21, 2025, at the SVIN annual meeting [2][3] Market Context - Aneurysmal subarachnoid hemorrhage (aSAH) accounts for approximately 5% of all strokes, with an estimated 42,500 hospital-treated patients in the U.S. annually [3]

Summary of Grace Therapeutics KOL Event on GTX-one 104 Company Overview - **Company Name**: Grace Therapeutics (formerly Acasti) [4][3] - **Product Focus**: GTX-one 104, a novel injectable formulation of nimodipine, in late-stage clinical development [3][4] Industry Context - **Target Indication**: Aneurysmal subarachnoid hemorrhage (ASAH) [4] - **Current Treatment Landscape**: Nimodipine is the only FDA-approved drug for neuroprotection in ASAH, available only in oral formulations [16][24] Key Points Discussed Clinical Development and Trials - **Pivotal Phase III Trial**: The STRIGON trial for GTX-one 104 was fully enrolled in September 2024, with data readout expected in Q1 2025 [4] - **Market Opportunity**: GTX-one 104 aims to address significant unmet needs in ASAH treatment, particularly due to limitations of current oral formulations [4][24] Disease Overview - **Prevalence and Impact**: Approximately 2% to 8% of the population has aneurysms, with a global incidence of ASAH around 6 per 100,000 person-years [9][10] - **Mortality Rates**: Pre-hospital mortality for aneurysm rupture is between 22% and 26%, with an additional 20% mortality for those reaching the hospital [11] Challenges with Current Treatment - **Limitations of Oral Nimodipine**: - Requires frequent dosing (60 mg every 4 hours) which can lead to hypotension in 25% of patients [32][30] - Many patients (30%) present with dysphagia, complicating oral administration [33] - Gastrointestinal intolerance affects up to 80% of patients, leading to complications like diarrhea [35] - Less than half of patients receive the full 21-day course, impacting outcomes [36] Advantages of GTX-one 104 - **Intravenous Formulation Benefits**: - Provides guaranteed drug exposure and allows for titratable dosing, addressing hypotension and absorption issues [42][39] - Flexibility in administration, especially for patients unable to take oral medications [40][42] - Consistent bioavailability, reducing variability in patient response [62] Clinical Implications - **Potential for Improved Outcomes**: Consistent exposure to nimodipine is linked to better functional outcomes, particularly in patients with higher-grade ASAH [39][45] - **Integration into Clinical Practice**: The introduction of GTX-one 104 could enhance treatment protocols in neurocritical care settings, where titratable IV medications are preferred [56][57] Additional Considerations - **Regulatory Pathway**: Approval of GTX-one 104 will require a review process by pharmacy and therapeutics committees, assessing clinical benefits and cost-effectiveness [43][44] - **Future Research**: Comparative studies may be necessary to establish the efficacy of GTX-one 104 against existing treatments [52][54] Conclusion - **Strategic Importance**: GTX-one 104 represents a significant advancement in the treatment of ASAH, addressing critical limitations of current therapies and potentially improving patient outcomes in a high-mortality condition [45][46]